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either (95% CI 5 0.19 to 48.75) and was barely so in tor for the excessive incidence of cardiovascular disease
(CVD) among dialysis patients, while calcitriol mightthe other two groups. Do the authors really recommend
reducing dialysis exposure (lower K and/or shorter t) for have an ameliorating effect [1]. I believe there is no
small and undernourished patients based on such weak evidence from controlled trials with clinical end points
information? for such a beneficial effect of vitamin D in these patients
Consider a 90-pound, malnourished adult female with (and very few trials with any clinical end points at all).
a V of 20 liters. Should clinicians be satisfied with total Referring to Milliner et al [2], they make the statement
treatment exposure of only 24 L/Rx because Kt/V 5 that excessive intake of vitamin D may lead to arterial
1.2? Existing information suggests that she would then calcification. This may not be a very practical definition
be at risk from both under-nutrition and under-dialysis of excessive intake. In fact, that article showed increasing
[4]. Further to the point, should clinicians reduce K and/ prevalence of systemic calcification as a function of
or t for a robust 70 kg male treated at Kt/V 5 1.2 if he any use of calcitriol [2]. A recent article found the
later becomes ill, losing substantial body mass, simply 1,25(OH)2D3 concentration to be the most important
to preserve Kt/V 5 1.2? The Doctors’ argument suggests predictor of progressive vascular calcification among
that doing otherwise would lead to “over-dialysis.” long time survivors on hemodialysis [3]. As the only
Finally, some legislators and regulators have suggested alternative to transplantation, increased dialysis may im-
that payment be denied for dialysis treatment if Kt/V , prove the positive phosphorus balance of current dialysis
1.2 in addition to other possible sanctions. That would patients [4]. Perhaps that would be the best way to pre-
apply mostly to larger patients. Should Medicare in the venting vitamin D and PTH related problems while
United States then refuse or reduce payment if Kt/V . maintaining a healthy nutrition, and so provide for long-
1.2 (mostly for smaller patients) because such treatment term survival (without calcitriol) as reported from Tas-
constitutes unnecessary “over-dialysis” and government sin, France.
rules forbid payment for unnecessary treatment? Thus, We might not be currently lacking the clinical stud-
we see emerging from the views expressed by Drs. Sala- ies—and be overwhelmed with experimental ones—if
hudeen and Fleischmann a number of currently implausi- those reviewing the individual parts of this patchwork
ble clinical (and possibly regulatory) strategies because constituting today’s dialysis therapy more appropriately
the mathematical model upon which they base their be- viewed the whole management of ESRD as perspective.
lief is not appropriate to the clinical context for which Troels Ring
it is used. Aalborg, Denmark
Edmund G. Lowrie
Correspondence to Troels Ring, M.D., Department of Nephrology,Fresenius Medical Care, Concord, MA, USA
Hobrovej 18-22, DK 9100, Aalborg, Denmark.
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Therapy for cardiovascular Reply from the authors
To the Editor: In his letter regarding our paper indisease in dialysis patients Kidney International reviewing the effects of parathyroid
hormone and vitamin D on cardiovascular disease inTo the Editor: Examining a number of experimental
chronic renal failure [1], Dr. Ring is surprised that theand observational studies, Rostand and Dru¨eke recently
burden of cardiovascular disease renal failure persists de-suggested that parathyroid hormone might be a risk fac-
spite the widespread use of active vitamin D in the man-
agement of hyperparathyroidism and hypocalcemia in
end-stage renal disease. As we noted, although some clini-Ó 2000 by the International Society of Nephrology
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cal studies have demonstrated regression of increased left in renal failure by producing vascular calcification, espe-
cially if used in low bone turnover states, or, if used aggres-ventricular mass index and amelioration of left ventricular
sively, thereby, in part, contributing to hypoparathyroid-performance following the use of calcitriol, there are no
ism, hypercalcemia, and hyperphosphatemia.large scale studies to confirm this premise. Moreover,
Vitamin D therapy in renal failure, if used earlycalcitriol has been shown to correct carbohydrate intoler-
enough, may reduce cardiovascular disease morbidityance, insulin resistance and hypertriglyceridemia in renal
and mortality in chronic renal failure. However, the tim-failure. Thus, at first glance, one might reasonably expect
ing of its initial use, the degree to which its use maycalcitriol therapy to dramatically reduce cardiovascular
be beneficial, and what risk factors it moderates mostmorbidity and mortality in renal failure. However, it must
significantly remain to be elucidated. Certainly, carefullybe remembered that, although nearly a universal problem
organized clinical trials to examine the impact of vitaminin renal failure, altered parathyroid hormone and vitamin
D treatment on cardiovascular disease would be impor-D status are only two of numerous cardiovascular risk
tant and of interest. Under any circumstances we recom-factors clustered in this patient population. Many of these
mend that vitamin D and its analogs be used rationallyexert effects on the cardiovascular system that may be
and should be avoided in case of hypercalcemia or hyper-
affected only partially, or not at all, by calcitriol. Second,
phosphatemia and when signs of low bone turnover or
many of the risk factors for cardiovascular disease in the hypoparathyroidism are present.
renal failure population may be present before renal dis-
Stephen G. Rostand and Tilman B. Dru¨eke
ease is manifest at a time when vitamin D supplementation
would not likely be considered. Third, cardiovascular REFERENCE
changes due to PTH excess may be irreversible and there-
1. Rostand SG, Dru¨eke TB: Parathyroid hormone, vitamin D, andfore not corrected by calcitriol therapy. Last, the use of cardiovascular disease in chronic renal failure. Kidney Int 56:383–
calcitriol may itself contribute to cardiovascular disease 392, 1999
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